Macro Finance
Sellas Life Sciences Surges 156% After Cancer Vaccine Data
Bloomberg Markets·November 17, 2026·1 min read
Sellas Life Sciences Group Inc. surged 156% after the drug developer reported positive late-stage trial results for an experimental cancer vaccine targeting an aggressive form of blood cancer. The data marks a significant milestone for the company, boosting investor confidence in its pipeline.
Read at Bloomberg MarketsDaily crypto arcade
Read the news, then play it.
Chainshorts turns crypto headlines into a daily game. Catch up in 60 words, then jump into daily lucky draws for a shot at the pot.